<DOC>
	<DOCNO>NCT02056015</DOCNO>
	<brief_summary>This study first-in-human ( FIH ) , single-dose , open-label , phase 1 study design assess safety , pharmacokinetics ( PK ) , distribution , radiation dosimetry [ 68Ga ] MLN6907 single intravenous ( IV ) administration . Patients Metastatic Colorectal Carcinoma schedule resection liver metastases part treatment plan eligible enrollment .</brief_summary>
	<brief_title>A Phase I Study MLN6907 Patients With Metastatic Colorectal</brief_title>
	<detailed_description />
	<mesh_term>Digestive System Neoplasms</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<criteria>Inclusion Criteria Each patient must meet follow inclusion criterion enrol study : Male female patient 18 year old . Must diagnose colorectal cancer ( CRC ) liver metastasis eligible schedule resection liver metastases part standard care treatment plan . The planned surgery must occur great 14 day day image . Patients must consent provide sponsor tumor tissue sample resect liver metastasis . Easter Cooperative Oncology Group ( ECOG ) performance status 0 1 . Female patient post menopausal , surgically sterile , agree practice effective method contraception time sign informed consent form 60 day dose [ 68Ga ] MLN6907 agree practice true abstinence . Male patient agree practice effective barrier contraception entire study treatment period 4 month dose [ 68Ga ] MLN6907 agree practice true abstinence . Voluntary write consent must give performance studyrelated procedure part standard medical care , understand consent may withdraw patient time without prejudice future medical care . Suitable venous access studyrequired , blood sampling ( ie , include PK sample ) Adequate hepatic function define protocol . Adequate renal function define protocol . Hemoglobin â‰¥ 9 g/dL . Recovery adverse effect prior antitumor therapy least Common Terminology Criteria Adverse Events ( CTCAE ) ( V4.03 ) Grade 1 . Exclusion Criteria Patients meeting follow exclusion criterion enrol study . Female patient lactate breastfeed positive serum pregnancy test screen period positive urine pregnancy test Day 1 first dose [ 68Ga ] MLN6907 . Any serious medical psychiatric illness , condition , personal circumstance , include severe claustrophobia , severe dyspnea , severe back pain , etc. , , judgment investigator project clinician , might potentially interfere procedure require study . Involvement investigative radioactive research procedure within 4 week prior administration [ 68Ga ] MLN6907 . Major surgery within 14 day prior administration [ 68Ga ] MLN6907 5 . Serious infection ( viral , bacterial , fungal ) within 14 day administration [ 68Ga ] MLN6907 evidence active infection screening . Lifethreatening illness unrelated cancer . Clinically significant central nervous system ( CNS ) metastases . Known inflammatory bowel disease . Known hepatitis B surface antigenpositive know suspect active hepatitis C infection ( test require ) . History hypersensitivity component [ 68Ga ] MLN6907 . Symptomatic cardiac disease , include ventricular dysfunction , coronary artery disease , arrhythmia , would , opinion investigator project clinician , interfere assessment efficacy safety [ 68Ga ] MLN6907 . Admission evidence addictive disorder ( eg , illicit drug use , drug abuse , alcohol abuse ) would limit compliance study requirement . Inability lie flat duration image acquisition .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>